Search results
Results from the WOW.Com Content Network
Increased risk of cancer. [32] Lumiracoxib (Prexige) 2007–2008 Worldwide Liver damage Lysergic acid diethylamide (LSD) 1950s–1960s Marketed as a psychiatric drug; withdrawn after it became widely used recreationally. Now illegal in most of the world. Mebanazine: 1975 UK Hepatotoxicity, drug intereaction. [3] Methandrostenolone: 1982
Luigi Di Bella (17 July 1912 in Linguaglossa – 1 July 2003 in Modena) was an Italian medical doctor and physiology professor. In the late 1980s, he created a disproven cancer treatment known as "Di Bella therapy" that precipitated an international controversy. [1] [2] Studies demonstrated that Di Bella's therapy for cancer is totally ineffective.
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source , are explained in Nomenclature of monoclonal antibodies .
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
The Italian Medicines Agency (Agenzia italiana del farmaco, AIFA) is the public institution responsible for the regulatory activity of pharmaceuticals in Italy. See also [ edit ]
Ukrain – the trademarked name of a drug (sometimes called "celandine") made from Chelidonium majus, a plant in the poppy family. The drug is promoted for its health giving powers and its ability to treat cancer; however, according to the American Cancer Society, "available scientific evidence does not support claims that celandine is ...
Many of the chemicals in these foods are already banned in most of Europe, and now several US states are following suit. In October, California passed the so-called Skittles Ban, which outlawed ...
The Prescribing Information follows one of two formats: "physician labeling rule" format or "old" (non-PLR) format. For "old" format labeling a "product title" may be listed first and may include the proprietary name (if any), the nonproprietary name, dosage form(s), and other information about the product. The other sections are as follows: